Overview of Semaglutide: From Research to Clinical Application
Semaglutide is classified as a GLP-1 receptor agonist, which mimics the effects of a hormone called glucagon-like peptide-1. This hormone is released naturally after eating, slows digestion, and promotes feelings of fullness.
GLP-1 receptor agonists like semaglutide were initially researched and developed as a treatment option for type 2 diabetes. By slowing digestion, these drugs help regulate blood sugar levels.
The first GLP-1 drug, exenatide, was approved for diabetes treatment in 2005. Development and testing continued over the years, leading to the creation of semaglutide.
In 2017, the FDA approved subcutaneous semaglutide injections. This novel medication showed better blood sugar control compared to other diabetes drugs.
But it wasn't long before researchers noticed another exciting benefit of semaglutide - significant weight loss. This prompted further clinical trials and the pursuit of FDA approval for treating chronic weight management.
In 2021, semaglutide was approved for long-term weight management in addition to diabetes treatment. The ability of this medication to deliver substantial, sustained weight loss has generated great enthusiasm in health communities.